Prestige Consumer Healthcare Inc. · NYSE:PBH
Prestige Consumer Healthcare — Q2 FY2027 Earnings Presentation
23 slides from Prestige Consumer Healthcare's earnings presentation, Nov 5, 2026
Slide 1: Second Quarter FY 2027 Results
Second Quarter FY 2027 Results November 5th, 2026 Exhibit 99.2
Slide 2: Safe Harbor Disclosure
S E C O N D Q U A R T E R F Y 2 7 R E S U L T S Safe Harbor Disclosure This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company’s expected financial performance, including reve
Slide 3: I. Performance Highlights
S E C O N D Q U A R T E R F Y 2 7 R E S U L T S I. Performance Highlights
Slide 4: Second Quarter Performance Exceeded Expectations
S E C O N D Q U A R T E R F Y 2 7 R E S U L T S Second Quarter Performance Exceeded Expectations ◼ Q2 revenue of $336.3 million, up 22.7% versus prior year — Organic revenue(1) decline of 1.6%, as expected, due to sales timing — First half organic revenue(1) growth of 0.7% — Base business consumptio
Slide 5: Acquisitions on Track; Key Brands Well Positioned for Success
S E C O N D Q U A R T E R F Y 2 7 R E S U L T S ◼ Own nighttime breathing and expand the user base ◼ New marketing campaign that builds on prior success ◼ Invest in adjacent opportunities like Sports ◼ Leverage in-house resources to accelerate innovation, distribution ◼ Operations largely consolidat
Slide 6: Ample LaCorium Opportunities Behind Dermal Therapy
S E C O N D Q U A R T E R F Y 2 7 R E S U L T S Ample LaCorium® Opportunities Behind Dermal Therapy® Proven History of Long-term Brand-Building, Generating Sales and Market Share Growth ✓ Extend “It Works” marketing campaign success 70%+ % of Sales Lip Care Foot Care Troubled Skin Hair & Scalp Perso
Slide 7: Strong Online Consumption Growth via Strategic Investments
S E C O N D Q U A R T E R F Y 2 7 R E S U L T S Strong Online Consumption Growth via Strategic Investments 7 ◼ History of consistent consumption performance across eCommerce ◼ Growing market share across strategic brands year-to-date *Year-over-year retail sales as of 10/6/2026 & fiscal year-end FY2
Slide 8: II. Financial Overview
S E C O N D Q U A R T E R F Y 2 7 R E S U L T S II. Financial Overview
Slide 9: Q2 FY27 Performance Highlights
S E C O N D Q U A R T E R F Y 2 7 R E S U L T S Q2 FY 27 Performance Highlights Q2 FY 27 Q2 FY 26 Dollar values in millions, except per share data. $336.3 $113.0 $1.13 $274.1 $86.8 $1.07 Revenue Adj. EBITDA Adj. Diluted EPS 22.7% 30.1% 5.6% Revenue of $336.3 million, up 22.7% vs. prior year Adjusted
Slide 10: Second Quarter and 1H Consolidated Financial Summary
S E C O N D Q U A R T E R F Y 2 7 R E S U L T S 3 Months Ended* First Half Comments FY27 Second Quarter and 1H Consolidated Financial Summary ◼ Revenue up 0.7% organically(1) versus prior year, as expected – North America segment up – Double-digit E-Commerce consumption growth – International segmen
Slide 11: Adjusted Free Cash Flow
S E C O N D Q U A R T E R F Y 2 7 R E S U L T S Adjusted Free Cash Flow(2) Comments ◼ Total 1H Adjusted Free Cash Flow(2) of $123.0 million down 8% vs. prior year due to working capital timing — Full-year adjusted free cash flow outlook(4) of $265 million or more — Strong business attributes continu
Slide 12: III. The Road Ahead
S E C O N D Q U A R T E R F Y 2 7 R E S U L T S III. The Road Ahead
Slide 13: Transition Year Sets Up Future Value Creation
S E C O N D Q U A R T E R F Y 2 7 R E S U L T S Transition Year Sets Up Future Value Creation Business Remains Well Positioned to Achieve Three-Year Algorithm Outlined in May Maintain marketing investments behind diversified, needs-based portfolio Stable organic growth across strategic brand portfol
Slide 14: Eye Care Recovery Path Remains Compelling
S E C O N D Q U A R T E R F Y 2 7 R E S U L T S Eye Care Recovery Path Remains Compelling Favorable Category Demand Outlook Iconic, Trusted Brand ◼ 50+ year Clear Eyes® heritage in redness relief ◼ Iconic, highly memorable evolved marketing ◼ History of market share wins prior to supply disruptions
Slide 15: Updated FY Outlook
S E C O N D Q U A R T E R F Y 2 7 R E S U L T S Updated FY 27 Outlook ◼ Revenues of $1,290 to $1,315 million — Organic growth of approximately 1% to 3% ◼ ~$190 million revenue anticipated from the Breathe Right and LaCorium acquisitions ◼ Revenues of approximately $1,280 to $1,290 million — Organic
Slide 16: Appendix
S E C O N D Q U A R T E R F Y 2 7 R E S U L T S Appendix
Slide 17: Appendix: Non-GAAP Footnotes
S E C O N D Q U A R T E R F Y 2 7 R E S U L T S Appendix (1) Organic Revenue is a Non-GAAP financial measure and is reconciled to the most closely related GAAP financial measure in the attached Reconciliation Schedules and / or our earnings release dated November 5, 2026 in the “About Non-GAAP Finan
Slide 18: Reconciliation Schedules: Organic Revenue Change
S E C O N D Q U A R T E R F Y 2 7 R E S U L T S 18 Reconciliation Schedules Organic Revenue Change (a) Revenues associated with Breathe Right® and LaCorium Health acquisitions are excluded for purposes of calculating Non-GAAP organic revenues. These revenue adjustments relate to our North America an
Slide 19: Reconciliation Schedules: Adjusted G&A and Gross Margin
S E C O N D Q U A R T E R F Y 2 7 R E S U L T S 19 Reconciliation Schedules (Continued) Adjusted G&A Expense (a) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees. Adjusted Gross Margin Three Months Ended September 30, Six Mont
Slide 20: Reconciliation Schedules: Adjusted EBITDA and EBITDA Margin
S E C O N D Q U A R T E R F Y 2 7 R E S U L T S 20 Reconciliation Schedules (Continued) Adjusted EBITDA and EBITDA Margin (a) Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly cons
Slide 21: Reconciliation Schedules: Adjusted Free Cash Flow
S E C O N D Q U A R T E R F Y 2 7 R E S U L T S 21 Reconciliation Schedules (Continued) Adjusted Free Cash Flow Projected Adjusted Free Cash Flow Three Months Ended September 30, Six Months Ended September 30, 2026 2025 2026 2025 (In Thousands) GAAP Net Income $25,295 $42,211 $54,472 $89,677 Adjustm
Slide 22: Reconciliation Schedules: Adjusted Net Income and Diluted EPS
S E C O N D Q U A R T E R F Y 2 7 R E S U L T S 22 Reconciliation Schedules (Continued) Adjusted Net Income & Adjusted Diluted EPS (a) Represents depreciation expense recorded during the remediation period following the acquisition of Pillar5, during which certain production lines were not operating
Slide 23: P C H C O N F I D E N T I A
P C H C O N F I D E N T I A L A N D P R O P R I E T A R Y I N F O R M A T I O N
Prestige Consumer Healthcare — Q2 FY2027 Earnings Presentation on 6ix